Recombinant Human PD-L1/B7-H1/CD274 Protein (Fc Tag)(Active)
SKU: PKSH031887-100
Recombinant Human PD-L1/B7-H1/CD274 Protein (Fc Tag)(Active)
SKU # | PKSH031887 |
Expression Host | HEK293 Cells |
Description
Synonyms | B7 homolog 1, B7-H1, B7H1, CD274, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, PDL1, Programmed Cell Death 1 Ligand 1, Programmed death ligand 1 |
Species | Human |
Expression Host | HEK293 Cells |
Sequence | Met 1-Thr 239 |
Accession | NP_054862.1 |
Calculated Molecular Weight | 52.0 kDa |
Observed Molecular Weight | 65-70 kDa |
Tag | C-hFc |
Bio-activity | Immobilized human PD-1 at 10 μg/ml (100 μl/well) can bind recombinant human B7-H1 / PD-L1 / Fc chimera with a linear range of 0.02-0.4 μg/ml. |
Properties
Purity | > 95 % as determined by reducing SDS-PAGE. |
Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method. |
Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
Formulation | Lyophilized from sterile PBS, pH 7.4 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
Reconstitution | Please refer to the printed manual for detailed information. |
Background
Programmed death-1 ligand-1 (PD-L1; CD274; B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain; and together with PD-L2; are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells; PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly; it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.